Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:ZBIO News 22 December 2025 - 6 January 2026

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma shares dropped 5.8% to $15.66 in premarket trading Tuesday, extending a 52% plunge after Phase 3 data for obexelimab in IgG4-related disease. The drug met its main goal but fell short of results seen with Amgen’s Uplizna, prompting Morgan Stanley to downgrade the stock and cut its price target. Zenas plans to file for FDA approval in Q2 2026.
6 January 2026
··
Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma shares were unchanged at $39.05 in premarket trading Tuesday after falling 8.1% Monday. The stock is down about 12% from its December 24 high as investors await Phase 3 INDIGO trial results expected around year-end. Monday’s session saw shares dip to $38.96 before closing at $39.05. Technical support is near $37.78, with resistance just above $41.
30 December 2025
·
Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma shares jumped about 14% to $41.23 on December 22, 2025, hitting a record high of $41.67 ahead of expected Phase 3 INDIGO trial results for obexelimab in IgG4-related disease. Citi and Wedbush both reiterated bullish ratings and price targets, citing the upcoming clinical data as a near-term catalyst.
22 December 2025
·

Stock Market Today

GigaDevice Semiconductor stock price: What to watch for 603986 A-shares as memory crunch bites

GigaDevice Semiconductor stock price: What to watch for 603986 A-shares as memory crunch bites

8 February 2026
GigaDevice Semiconductor’s Class A shares closed at 276.17 yuan in Shanghai, down 0.6% Friday. The company faces a Feb. 11 shareholder vote on related-party transaction limits and an overseas auditor. Investors are watching for fallout from the global memory-chip shortage, which has pushed prices higher across the supply chain. GigaDevice’s shares have nearly doubled over the past year.
Astera Labs (ALAB) stock closes near $170 after 19% jump as earnings week looms

Astera Labs (ALAB) stock closes near $170 after 19% jump as earnings week looms

8 February 2026
Astera Labs shares jumped 18.9% to $169.85 Friday, trading as high as $170.01 on volume of 7.3 million. The move followed Amazon’s AI spending forecast and a nearly 6% gain in the PHLX Semiconductor Index. Astera reports fourth-quarter results Tuesday after market close, with revenue guidance at $245–$253 million.
Sungrow Power Supply (300274.SZ) A-shares: Monday watch after “commercial space” denial

Sungrow Power Supply (300274.SZ) A-shares: Monday watch after “commercial space” denial

8 February 2026
Sungrow closed at 144.50 yuan, down 1.03%, after stating it has no plans in the commercial space sector. Mainland China trading resumes Monday, with Spring Festival closures set for Feb. 15–23. Major funds were net sellers of 5.46 billion yuan on Feb. 6. The Shenzhen-listed solar firm remains under scrutiny as investors await further filings before the holiday.
MPWR stock price hits a new high after Monolithic Power’s outlook — what traders watch next week

MPWR stock price hits a new high after Monolithic Power’s outlook — what traders watch next week

8 February 2026
Monolithic Power Systems shares surged 6.4% to $1,229.82 Friday, hitting a new 52-week high after raising its dividend to $2.00 and forecasting first-quarter revenue of $770 million to $790 million. CEO Michael Hsing filed a Rule 144 notice for 3,082 shares. CFO Bernie Blegen will retire after the 2025 annual report, with Rob Dean named interim CFO. Fourth-quarter revenue rose 20.8% to $751.2 million.
Go toTop